X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs ASTRAZENECA PHARMA - Comparison Results

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA ASTRAZENECA PHARMA NATCO PHARMA/
ASTRAZENECA PHARMA
 
P/E (TTM) x 19.7 142.9 13.8% View Chart
P/BV x 18.9 21.7 87.0% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 NATCO PHARMA   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
ASTRAZENECA PHARMA
Mar-14
NATCO PHARMA/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs8771,285 68.2%   
Low Rs424634 66.8%   
Sales per share (Unadj.) Rs223.4189.6 117.9%  
Earnings per share (Unadj.) Rs31.1-0.2 -15,259.1%  
Cash flow per share (Unadj.) Rs40.33.8 1,047.6%  
Dividends per share (Unadj.) Rs5.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs219.568.6 319.8%  
Shares outstanding (eoy) m33.0725.00 132.3%   
Bonus/Rights/Conversions PA--  
Price / Sales ratio x2.95.1 57.5%   
Avg P/E ratio x20.9-4,712.7 -0.4%  
P/CF ratio (eoy) x16.1249.6 6.5%  
Price / Book Value ratio x3.014.0 21.2%  
Dividend payout %16.10-   
Avg Mkt Cap Rs m21,50423,988 89.6%   
No. of employees `000NA1.6 0.0%   
Total wages/salary Rs m1,1281,605 70.3%   
Avg. sales/employee Rs ThNM3,040.2-  
Avg. wages/employee Rs ThNM1,029.2-  
Avg. net profit/employee Rs ThNM-3.3-  
INCOME DATA
Net Sales Rs m7,3894,740 155.9%  
Other income Rs m16792 181.4%   
Total revenues Rs m7,5564,832 156.4%   
Gross profit Rs m1,793-130 -1,381.6%  
Depreciation Rs m304101 300.8%   
Interest Rs m3660-   
Profit before tax Rs m1,290-139 -928.6%   
Minority Interest Rs m460-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0139 0.0%   
Tax Rs m3095 6,064.8%   
Profit after tax Rs m1,027-5 -20,184.7%  
Gross profit margin %24.3-2.7 -886.2%  
Effective tax rate %23.9-3.7 -653.1%   
Net profit margin %13.9-0.1 -12,947.7%  
BALANCE SHEET DATA
Current assets Rs m3,6812,726 135.0%   
Current liabilities Rs m3,1232,435 128.2%   
Net working cap to sales %7.66.1 123.0%  
Current ratio x1.21.1 105.3%  
Inventory Days Days8974 121.3%  
Debtors Days Days5941 144.0%  
Net fixed assets Rs m7,6851,035 742.3%   
Share capital Rs m33150 661.4%   
"Free" reserves Rs m6,670942 707.7%   
Net worth Rs m7,2591,716 423.0%   
Long term debt Rs m9550-   
Total assets Rs m11,9574,156 287.7%  
Interest coverage x4.5NM-  
Debt to equity ratio x0.10-  
Sales to assets ratio x0.61.1 54.2%   
Return on assets %11.7-0.1 -9,516.3%  
Return on equity %14.2-0.3 -4,771.7%  
Return on capital %20.70-  
Exports to sales %39.45.7 690.3%   
Imports to sales %5.76.5 88.2%   
Exports (fob) Rs m2,908270 1,076.2%   
Imports (cif) Rs m421306 137.5%   
Fx inflow Rs m3,445375 919.8%   
Fx outflow Rs m703470 149.5%   
Net fx Rs m2,743-96 -2,870.3%   
CASH FLOW
From Operations Rs m1,440-8 -17,781.5%  
From Investments Rs m-1,089-146 747.6%  
From Financial Activity Rs m-353862 -40.9%  
Net Cashflow Rs m-1709 -0.2%  

Share Holding

Indian Promoters % 52.0 0.0 -  
Foreign collaborators % 1.5 75.0 2.0%  
Indian inst/Mut Fund % 7.8 0.3 2,613.3%  
FIIs % 16.6 15.7 105.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 9.1 285.7%  
Shareholders   25,395 12,856 197.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   GLENMARK PHARMA  FULFORD INDIA  MERCK LTD  DIVIS LABORATORIES  UNICHEM LAB  

Compare NATCO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

OPEC Meeting; Upcoming IPOs; IDBI Bank, Emami among Top Stocks in Action Today(Pre-Open)

Indian share markets edged up on Friday with Nifty 50 closing above 10,800-levels, even as broader global markets remained weak.

Related Views on News

NATCO PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 69.6%

May 25, 2018 | Updated on May 25, 2018

For the quarter ended March 2018, NATCO PHARMA has posted a net profit of Rs 3 bn (up 69.6% YoY). Sales on the other hand came in at Rs 8 bn (up 32.9% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

This Behaviour is Injurious to Wealth Building(Sector Info)

Jun 13, 2018

Blindly following the herd can be the biggest wealth destroyer.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Jun 25, 2018 09:37 AM

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 5-YR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS